(Z)-5-(4-(benzyloxy)benzylidene)-4-hydroxythiazole-2(5H)-thione | 181765-57-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: (Z)-5-(4-(benzyloxy)benzylidene)-4-hydroxythiazole-2(5H)-thione
• CAS: 181765-57-1
• 化学式: C₁₇H₁₃NO₂S₂
• mdl: MFCD00300331
• 分子量: 327.4
• InChiKey: LNPKMUHSBCXBNB-GDNBJRDFSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.3
• 重原子数：
  22
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.058
• 拓扑面积：
  95.7
• 氢给体数：
  1
• 氢受体数：
  4

文献信息

• Novel ligands for the hisb10 zn2+ sites of the r-state insulin hexamer
  申请人：——

  公开号：US20030229120A1

  公开（公告）日：2003-12-11

  Novel ligands for the HisB10 Zn 2+ sites of the R-state insulin hexamer that are capable of prolonging the action of insulin preparations are disclosed.

  揭示了能够延长胰岛素制剂作用的R-态胰岛素六聚体的HisB10 Zn2+位点的新配体。
• Benzylidene rhodanines
  申请人：Eli Lilly and Company

  公开号：US05747517A1

  公开（公告）日：1998-05-05

  This invention provides novel benzylidene rhodanines which are useful as agents in treating or preventing conditions associated with .beta.-amyloid peptide. This invention further provides methods of treating or preventing Alzheimer's Disease which comprises administering to a mammal in need thereof an effective amount of one or more of the benzylidene rhodanines of the present invention.

  本发明提供了一种新型的苄亚胺硫代缩苹果酸，它们作为治疗或预防与β-淀粉样肽相关疾病的药物很有用。本发明还提供了治疗或预防阿尔茨海默病的方法，该方法包括向需要的哺乳动物施用有效量的本发明的一种或多种苄亚胺硫代缩苹果酸。
• Molecular modeling of drug-pathophysiological Mtb protein targets: Synthesis of some 2-thioxo-1, 3-thiazolidin-4-one derivatives as anti-tubercular agents
  作者：K.M. Noorulla、Ayyadurai Jerad Suresh、Vinod Devaraji、Bijo Mathew、Devi Umesh

  DOI：10.1016/j.molstruc.2017.07.009

  日期：2017.11

  novel 2 - thioxo - 1 , 3 - thiazolidin - 4 - one derivatives ( 5a - 5t ) were synthesized and evaluated for their antitubercular activity. The structure of the compounds was confirmed by IR, NMR and Mass Spectroscopy methods. In addition, single-crystal X-ray diffraction was performed for compound 5a . All the synthesized compounds were screened for their in - vitro antimycobacterial activity against

  摘要 合成了20种新型2-thioxo-1,3-thiazolidin-4-one衍生物(5a-5t)并评价了它们的抗结核活性。化合物的结构通过红外、核磁共振和质谱方法确认。此外，对化合物5a进行了单晶X射线衍射。所有合成的化合物均通过 Alamar Blue 测定法筛选其对 MTB（H37RV，ATCC 编号：27294）的体外抗分枝杆菌活性。化合物5r、5k、5t显示出最有效的体外活性，MIC分别为0.05、0.1、0.2μg/ml浓度，其比标准品更有效。进行分子对接和动力学模拟以找出标题化合物的合理机制。
• [EN] PHAMACEUTICAL PREPARATIONS COMPRISING INSULIN<br/>[FR] PREPARATIONS PHARMACEUTIQUES CONTENANT DE L'INSULINE
  申请人：NOVO NORDISK AS

  公开号：WO2006005683A1

  公开（公告）日：2006-01-19

  Novel preparations comprising ligands for the HisB10 Zn2+ sites of the R-state insulin hexamer wherein the ligand is extended by protamine that are capable of prolonging the ac­tion of insulin preparations.

  新型制剂包括配体，用于R-态胰岛素六聚体的HisB10 Zn2+位点，其中配体通过精氨酸延长，能够延长胰岛素制剂的作用。
• Stabilised insulin compositions
  申请人：Kaarsholm Christian Niels

  公开号：US20050065066A1

  公开（公告）日：2005-03-24

  The present invention provides pharmaceutical compositions comprising insulin and novel ligands for the His B10 Zn 2+ sites of the R-state insulin hexamer. The resulting preparations have improved physical and chemical stability.

  本发明提供了包含胰岛素和新型配体的药物组合物，用于R-态胰岛素六聚体的His B10 Zn2+位点。由此制备的药物具有改善的物理和化学稳定性。